chartexchange

Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

Business Wire | Nov 12, 2026 8:00 AM EST

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on other recent business achievements. Recent Business Highlights On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycyt

Read original article